LLY
LLY
NYSE · Pharmaceuticals

Eli Lilly and Co.

S&P 500 Mega-Cap Stocks Blue Chip Stocks Pharmaceutical Stocks Healthcare Stocks Best Dividend Stocks
$948.45
-26.51 (-2.72%)
As of May 8, 9:30 PM ET ·
Financial Highlights (FY 2026)
Revenue
68.71B
Net Income
21.76B
Gross Margin
83.0%
Profit Margin
31.7%
Rev Growth
+31.7%
D/E Ratio
1.60
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 83.0% 83.0% 56.4% 56.4%
Operating Margin 40.3% 36.3% 27.5% 24.1%
Profit Margin 31.7% 30.1% 18.8% 23.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 68.71B 52.17B 262.19B 288.72B
Gross Profit 57.06B 43.33B 147.80B 162.76B
Operating Income 27.72B 18.95B 72.23B 69.71B
Net Income 21.76B 14.87B 49.23B 68.90B
Gross Margin 83.0% 83.0% 56.4% 56.4%
Operating Margin 40.3% 36.3% 27.5% 24.1%
Profit Margin 31.7% 30.1% 18.8% 23.9%
Rev Growth +31.7% +31.7% +3.8% -0.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 281.12B 281.12B 59.02B 45.19B
Total Equity 175.50B 175.50B 657.24B 666.99B
D/E Ratio 1.60 1.60 0.09 0.07
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 29.23B 21.09B 80.48B 106.53B
Free Cash Flow — — 35.91B 45.81B